This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Trump demands Big Pharma rein in 'abusive drug pricing practices'

( July 31, 2025, 22:27 GMT | Official Statement) -- MLex Summary: If Pfizer, Novo Nordisk, Eli Lil and 14 other leading drugmakers don't "step up" by implementing drug cost reduction measures that include guaranteeing "most-favored nation" pricing for newly-launched drugs to Medicare, Medicaid and commercial payers, the federal government "will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices" US President Donald Trump said in letters to company leaders. "Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices and an end to the free ride of American innovation by European and other developed nations," Trump said in a letter to Eli Lilly Chief Executive David Ricks. Statement follows below. See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections